{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:09:39Z","timestamp":1792076979731,"version":"4.4.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"41","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:00:00Z","timestamp":1693008000000},"content-version":"am","delay-in-days":359,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007428","name":"Naito Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21fk0108141"],"award-info":[{"award-number":["21fk0108141"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20fk0108411"],"award-info":[{"award-number":["JP20fk0108411"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20nk0101603"],"award-info":[{"award-number":["JP20nk0101603"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20nk0101604"],"award-info":[{"award-number":["JP20nk0101604"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20nk0101626"],"award-info":[{"award-number":["JP20nk0101626"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21fk0108083"],"award-info":[{"award-number":["JP21fk0108083"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.vaccine.2022.08.049","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T02:49:04Z","timestamp":1661482144000},"page":"5892-5903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology"],"prefix":"10.1016","volume":"40","author":[{"given":"Takuya","family":"Hemmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3054-8846","authenticated-orcid":false,"given":"Akira","family":"Ainai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Hashiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Tobiume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Kanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Iwata-Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2927-1149","authenticated-orcid":false,"given":"Yuko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Shiwa-Sudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyo","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10223","key":"10.1016\/j.vaccine.2022.08.049_b0005","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.vaccine.2022.08.049_b0010","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.vaccine.2022.08.049_b0015","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2022.08.049_b0020","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"10269","key":"10.1016\/j.vaccine.2022.08.049_b0025","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0140-6736(20)32623-4","article-title":"Oxford-AstraZeneca COVID-19 vaccine efficacy","volume":"397","author":"Knoll","year":"2021","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.vaccine.2022.08.049_b0030","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.08.049_b0035","unstructured":"Medicines and Healthcare products Regulatory Agency. UK medicines regulator gives approval for first UK COVID-19 vaccine., https:\/\/www.gov.uk\/government\/news\/uk-medicines-regulator-gives-approval-for-first-uk-covid-19-vaccine; 2020 [accessed 15 May 2022]."},{"issue":"5","key":"10.1016\/j.vaccine.2022.08.049_b0040","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0264-410X(88)90140-5","article-title":"Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit","volume":"6","author":"Tamura","year":"1988","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2022.08.049_b0045","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0264-410X(90)90250-P","article-title":"Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza","volume":"8","author":"Tamura","year":"1990","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.08.049_b0050","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/eji.1830210602","article-title":"Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules","volume":"21","author":"Tamura","year":"1991","journal-title":"Eur J Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.08.049_b0055","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.4049\/jimmunol.168.6.2930","article-title":"Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines","volume":"168","author":"Asahi","year":"2002","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.08.049_b0060","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/jmv.20173","article-title":"Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus","volume":"74","author":"Asahi-Ozaki","year":"2004","journal-title":"J Med Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2022.08.049_b0065","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1128\/JVI.79.5.2910-2919.2005","article-title":"Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection","volume":"79","author":"Ichinohe","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.08.049_b0070","unstructured":"World Health Organization. Interim Statement on COVID-19 vaccines in the context of the circulation of the Omicron SARS-CoV-2 Variant from the WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC), https:\/\/www.who.int\/news\/item\/11-01-2022-interim-statement-on-covid-19-vaccines-in-the-context-of-the-circulation-of-the-omicron-sars-cov-2-variant-from-the-who-technical-advisory-group-on-covid-19-vaccine-composition; 2022 [accessed 6 May 2022]."},{"key":"10.1016\/j.vaccine.2022.08.049_b0075","unstructured":"World Health Organization. The COVID-19 vaccine tracker and landscape compiles detailed information of each COVID-19 vaccine candidate in development by closely monitoring their progress through the pipeline., https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines; 2022 [accessed 6 May 2022]."},{"key":"10.1016\/j.vaccine.2022.08.049_b0080","doi-asserted-by":"crossref","first-page":"103841","DOI":"10.1016\/j.ebiom.2022.103841","article-title":"Intranasal COVID-19 vaccines: From bench to bed","volume":"76","author":"Alu","year":"2022","journal-title":"EBioMedicine"},{"issue":"23","key":"10.1016\/j.vaccine.2022.08.049_b0085","doi-asserted-by":"crossref","first-page":"12201","DOI":"10.1128\/JVI.06048-11","article-title":"A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge","volume":"85","author":"Bolles","year":"2011","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2022.08.049_b0090","doi-asserted-by":"crossref","first-page":"e35421","DOI":"10.1371\/journal.pone.0035421","article-title":"Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus","volume":"7","author":"Tseng","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.vaccine.2022.08.049_b0095","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.4049\/jimmunol.181.9.6337","article-title":"Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV","volume":"181","author":"Yasui","year":"2008","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.049_b0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/1348-0421.12754","article-title":"Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs","volume":"64","author":"Sekimukai","year":"2020","journal-title":"Microbiol Immunol"},{"issue":"15","key":"10.1016\/j.vaccine.2022.08.049_b0105","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1128\/JVI.00983-14","article-title":"Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB\/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine","volume":"88","author":"Iwata-Yoshikawa","year":"2014","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.08.049_b0110","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1128\/JVI.02980-14","article-title":"Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology","volume":"89","author":"Honda-Okubo","year":"2015","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.049_b0115","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh3827","article-title":"A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection","volume":"8","author":"Iwata-Yoshikawa","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2022.08.049_b0120","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am J Epidemiol"},{"issue":"9","key":"10.1016\/j.vaccine.2022.08.049_b0125","doi-asserted-by":"crossref","first-page":"103037","DOI":"10.1016\/j.isci.2021.103037","article-title":"Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2","volume":"24","author":"An","year":"2021","journal-title":"iScience"},{"issue":"16","key":"10.1016\/j.vaccine.2022.08.049_b0130","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/j.vaccine.2021.03.006","article-title":"Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse","volume":"39","author":"Du","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.08.049_b0135","unstructured":"U.S. Food and Drug Administration. Development and licensure of vaccines to prevent COVID-19, https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/development-and-licensure-vaccines-prevent-covid-19; 2020 [accessed 6 May 2022]."},{"key":"10.1016\/j.vaccine.2022.08.049_b0140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.803090","article-title":"S-540956, a CpG Oligonucleotide Annealed to a Complementary Strand With an Amphiphilic Chain Unit, Acts as a Potent Cancer Vaccine Adjuvant by Targeting Draining Lymph Nodes","volume":"12","author":"Nakagawa","year":"2021","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2022.08.049_b0145","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41591-020-0913-5","article-title":"A serological assay to detect SARS-CoV-2 seroconversion in humans","volume":"26","author":"Amanat","year":"2020","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.vaccine.2022.08.049_b0150","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/j.immuni.2021.08.025","article-title":"A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site","volume":"54","author":"Onodera","year":"2021","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.vaccine.2022.08.049_b0155","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1073\/pnas.1718957115","article-title":"Structures of the prefusion form of measles virus fusion protein in complex with inhibitors","volume":"115","author":"Hashiguchi","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6510","key":"10.1016\/j.vaccine.2022.08.049_b0160","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.abd0826","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 spikes","volume":"369","author":"Hsieh","year":"2020","journal-title":"Science"},{"issue":"7815","key":"10.1016\/j.vaccine.2022.08.049_b0165","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.vaccine.2022.08.049_b0170","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.immuni.2021.06.015","article-title":"Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants","volume":"54","author":"Moriyama","year":"2021","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.vaccine.2022.08.049_b0175","doi-asserted-by":"crossref","first-page":"e0215822","DOI":"10.1371\/journal.pone.0215822","article-title":"Consensus and variations in cell line specificity among human metapneumovirus strains","volume":"14","author":"Nao","year":"2019","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.vaccine.2022.08.049_b0180","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1073\/pnas.2002589117","article-title":"Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells","volume":"117","author":"Matsuyama","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.049_b0185","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20653-8","article-title":"SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice","volume":"12","author":"Tian","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.vaccine.2022.08.049_b0190","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1165\/rcmb.2013-0086MA","article-title":"Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung","volume":"49","author":"Misharin","year":"2013","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.vaccine.2022.08.049_b0195","article-title":"Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8(+) T cell responses","volume":"3","author":"Ishii","year":"2022","journal-title":"Cell Rep Med"},{"issue":"4","key":"10.1016\/j.vaccine.2022.08.049_b0200","doi-asserted-by":"crossref","first-page":"109452","DOI":"10.1016\/j.celrep.2021.109452","article-title":"An intranasal vaccine durably protects against SARS-CoV-2 variants in mice","volume":"36","author":"Hassan","year":"2021","journal-title":"Cell Rep"},{"issue":"8","key":"10.1016\/j.vaccine.2022.08.049_b0205","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1084\/jem.187.8.1193","article-title":"T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching","volume":"187","author":"Toellner","year":"1998","journal-title":"J Exp Med"},{"issue":"11","key":"10.1016\/j.vaccine.2022.08.049_b0210","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1128\/AAC.39.11.2574","article-title":"Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice","volume":"39","author":"Wong","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.vaccine.2022.08.049_b0215","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1128\/JVI.01805-09","article-title":"Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model","volume":"84","author":"Norton","year":"2010","journal-title":"J Virol"},{"issue":"70","key":"10.1016\/j.vaccine.2022.08.049_b0220","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abn8590","article-title":"SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine","volume":"7","author":"Kotaki","year":"2022","journal-title":"Sci Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2022.08.049_b0225","doi-asserted-by":"crossref","first-page":"100603","DOI":"10.1016\/j.xcrm.2022.100603","article-title":"Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination","volume":"3","author":"Mantus","year":"2022","journal-title":"Cell Rep Med"},{"issue":"4","key":"10.1016\/j.vaccine.2022.08.049_b0230","first-page":"249","article-title":"Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants","volume":"3","author":"Miyamoto","year":"2022","journal-title":"Med (NY)"},{"issue":"7902","key":"10.1016\/j.vaccine.2022.08.049_b0235","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41586-022-04441-6","article-title":"SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters","volume":"603","author":"Halfmann","year":"2022","journal-title":"Nature"},{"issue":"7902","key":"10.1016\/j.vaccine.2022.08.049_b0240","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41586-022-04479-6","article-title":"SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo","volume":"603","author":"Hui","year":"2022","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.vaccine.2022.08.049_b0245","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.immuni.2014.10.004","article-title":"T follicular helper cell differentiation, function, and roles in disease","volume":"41","author":"Crotty","year":"2014","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.vaccine.2022.08.049_b0250","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.immuni.2021.01.014","article-title":"B cell memory: understanding COVID-19","volume":"54","author":"Quast","year":"2021","journal-title":"Immunity"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22010386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22010386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:17:53Z","timestamp":1759403873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22010386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":50,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0264410X22010386"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.08.049","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.05.24.493348","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.08.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}